Completed PHASE2 INTERVENTIONAL 2-arm NCT01848730

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia

A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia

Sponsor: Convergence Pharmaceuticals

Conditions Post-herpetic Neuralgia

Interventions CNV2197944 Placebo

Updated 5 times since 2017 Last updated: Oct 29, 2014 Started: Apr 30, 2013 Primary completion: Feb 28, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Post-herpetic Neuralgia, this trial is completed. The trial is conducted by Convergence Pharmaceuticals and has accumulated 5 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Convergence Pharmaceuticals

Data source: Convergence Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cape Town, South Africa